INTRODUCTION
The autoimmune disease, systemic lupus erythematosus (SLE) includes a range of manifestations from skin rashes, chronic fatigue and arthritis to the more severe glomerulonephritis, serositis and neurological involvement. Although improved monitoring and earlier diagnosis have had great impact on prognosis, progress in treatment has not been as significant as for some other rheumatic diseases such as rheumatoid arthritis. SLE still causes disease flares in the patients and leads to irreversible organ damage over time (1) . SLE affects approximately 70 per 100 000 but varies between countries, populations and genders with a 6-10 times increased frequency in women (2) . Early during the disease, infections pose the largest threat whereas as the disease progresses, vascular diseases such as myocardial infarction or stroke can become up to 10 times more common compared to normal (3) .
Autoantibodies directed against DNA and histones (4) are commonly found in SLE are thought to cause many of the manifestations. The autoantibodies induce complement activation but also a general Fc gamma receptor (FcR) mediated immune reaction (5) . More importantly, the autoantibodies form immune complexes (ICs) that deposit in the kidney glomeruli. These ICs effectively activate the classical complement pathway and cause tissue damage, which leads to lupus nephritis (LN) (6) . Interestingly, patients with SLE display elevated levels of autoantibodies several years before outbreak of the disease, which indicates an early loss of tolerance. Often, antibodies against SSA are detected first whereas antibodies against DNA are detected closer to disease outbreak (7, 8) .
The complement cascade is a part of the innate immune system (9) . Genetic deficiency of the initiator of the classical pathway, C1q predisposes strongly to SLE.
Deficiencies or mutations in other complement proteins of the classical pathway, such as C1r, C1s, C4 and C2 also increase the risk although to a lower extent compared to C1q. It was initially suggested that SLE development in C1q deficient patients was due to a reduced ability to clear apoptotic cells since C1q is an important opsonin of such cells. However, new exciting roles for C1q and other complement proteins in SLE have since emerged. In this review we explore the latest developments in complement research, focusing on SLE and highlighting areas where research has progressed during the last couple of years (also summarized in figure 1 ). We hence aim to provide the reader with an updated view of this exciting field.
Genetic associations
The genetic predisposition is evident in SLE and close relatives to patients have an increased risk of developing the disease. However, the concordance for homozygous twins is only 24% (10) which indicates there is also a strong environmental impact on disease. Apart from genes encoding certain MHC variants (11) , genetic deficiencies of many classical pathway components are strongly associated with development of SLE (12) see online supplementary (Table S1 ). This is paradoxical since complement is thought to contribute to the inflammatory tissue destruction observed in SLE (13) .
However, the classical pathway of complement is important for preventing SLE but once the disease is established, complement may amplify the disease (14, 15) .
C1q associations
Although only less than 70 cases have been reported, almost all patients with C1q deficiency develop SLE. C1q deficiency not only overrides the sex predisposition but also often causes early onset of the disease in childhood. Two novel mutations in C1qA and the C1qB gene were recently found to cause C1q deficiency (16) (17) adding to previously reported mutations (18) . Another mutation in the C1q genes renders a functional defect. The C1q can still bind to apoptotic cells but fails to assemble with C1r and C1s and hence fails to activate complement (19) . Interestingly, phagocytosis is also decreased, indicating that other complement proteins than C1q itself (C2, C4, C3) may be important for proper phagocytosis. Common variants of C1q may also be associated with certain SLE manifestations such as photosensitivity and nephritis (20) . However, these associations may be population specific and do not associate with SLE diagnosis but only with specific manifestations (21) . Restoring C1q levels by plasma transfusion in C1q deficient patient ameliorates the pathology (22) and recently a C1q deficient patient with SLE was cured with bone marrow transplantation reconstituting C1q, which is produced mainly in macrophages (23) .
C2 and C4 associations C2 deficiency has a frequency of 1 in 20 000 and increases the risk of infections and SLE with antibodies against C1q and cardiolipin (24). In the C2 gene, a 28 bp deletion is commonly associated with SLE in Caucasians (25), but not in a small Malaysian population (26). C4 is expressed in two isoforms C4A and C4B. Complete C4 deficiencies are rare but variations in gene copy number are common and affect plasma levels. As a physician, this is important to keep in mind when using C4 levels to monitor disease activity (24). Low gene copy numbers of the C4A gene increase the risk of SLE in a Korean population whereas increased gene copy numbers are protective (27). On the other hand, copy numbers of the C4B gene are not associated with SLE (28). By using multiple cohorts from northern and southern Europe a recent study could however not find any protective effects of C4A. Although they established that complete C4 deficiency was a risk factor, partial C4 deficiency was dependent on its genetic localization, which is close to the strongly associated HLA haplotypes (29). 
C1q antibodies
Autoantibodies against C1q in SLE are commonly observed (43, 44) . C1q antibodies could result in decreased C1q levels, mimicking a C1q deficient state with impaired clearance of dying cells (45) . Whether the antibodies are directed at C1q or simply cross-reacting due to antigen resemblance is a matter of debate (46) . The level of C1q
antibodies is a good predicative marker for LN (47, 48) C1q opsonizes apoptotic cells (55) , however the C1q receptor on the phagocyte is still a matter of controversy (56) . A recent study described the scavenging receptor SCARF1 as a C1q dependent receptor for clearance of apoptotic cells (57). C1q is not only an important opsonin but further acts to ensure silent removal of the apoptotic cells by preventing inflammasome assembly (58).
To further prevent unwanted inflammation, complement inhibitors such as and C4b-binding protein are also present on apoptotic cells (59) . Autoantibodies against FH however, do not seem to be a common feature in SLE (60) 
T cells
Lately the importance of complement in T cell regulation has received attention (76).
C3d can alter T cell function and C3d deposition was found to cause less intracellular Ca 2+ release in T cells, which led to increased production of inflammatory cytokines 
Complement and lupus nephritis
Complement plays a major role in multiple kidney diseases (90) and so also in LN.
An important function for complement is to remove IC from circulation. This is achieved by binding of ICs to complement receptor 1 (CR1) expressed on the erythrocytes (91). In LN, deposits of ICs in the glomeruli are regularly found and these activate complement in the kidneys. As such, this pathologic finding (C4d + ICs) in kidney biopsy is a strong evidence for diagnosis of SLE. In LN, C4d deposition is common, however, little correlation of C4d-deposition in the kidneys
and SLE activity appears to exist (92) . This is maybe not surprising since ICs are found in glomeruli in patients even without manifestations indicating LN. C3b-deposition in the kidneys is however a good marker for LN and a MRI based study explored the possibility to non-invasively detect C3b-deposition in kidneys to monitor LN progression in mice (93) . Antibodies against DNA and C1q are regularly found in glomerular IC deposits and these antibodies co-localize with antibodies to CRP in a small recent study on kidney biopsies (94) .
Complement and thrombosis
A long-term consequence of SLE is an elevated risk for cardiovascular disease.
Venous thrombosis may also occur early in SLE and is associated with the presence of antibodies against cardiolipin (95, 96) . A recent study in SLE patients has pointed out that increased complement levels correlate with increased levels of HDL in plasma and early signs of atherosclerosis such as thickening of the heart vessel wall (97) . This is puzzling since low complement levels are common in SLE patients although the risk for cardiovascular disease is increased. Complement activation products on platelets may instead explain the elevated risk of thrombosis as a consequence of platelet activation (98) . Complement may also contribute to thrombosis in antiphospholipid syndrome, which is a common secondary syndrome to SLE. In antiphospholipid syndrome, complement may also be involved in the common complications observed during pregnancy (99) .
Complement in diagnostics and therapeutics
Complement levels are easily measured in serum but caution should be taken due to easily occurring in vitro activation. Complement serum levels further do not differentiate between consumption and production, which may be important for diagnosis. Despite this they do provide a good and well-established tool to monitor SLE activity, and measurements of C3 and C4 are used worldwide and also included in some disease activity indexes such as SLEDAI. Levels of C1q are less widely used but can be of great value for monitoring LN activity. Disturbingly, there are rather large differences in detection methods as is apparent in a recent comparative study including also detection of DNA antibodies (100). Instead, complement deposition on immune cells may be used as more robust method to monitor SLE and LN activity (101, 102) . The usefulness of these for actual SLE diagnosis may however be questioned. Instead a panel of parameters including C4d-deposition on B-cells and erythrocytes has been suggested (103) . Since activation of complement contributes to disease activity, therapeutics such as a monoclonal antibody against C5 (eculizumab)
that blocks the pro-inflammatory activation of complement has been tested with promising results in a murine lupus model (104) . However, when one injection of eculizumab was given to 24 SLE patients with low disease activity no clinical effect or side effects were observed within 2 months of observation (105) . Based on the success of eculizumab in treatment of aHUS (106) and dense deposits disease (107) this and other drugs aiming to inhibit complement such as compstatin (108) 
